Information Provided By:
Fly News Breaks for January 22, 2019
LGND
Jan 22, 2019 | 08:39 EDT
Craig-Hallum analyst Matt Hewitt believes the bear thesis on Ligand misses the net. The analyst sees "tremendous value" in Ligand and encourages investors to take advantage of this "great entry point." Hewitt believes that the company's pipeline will continue to mature and deliver additional approvals, and thinks the real value lies in the royalty streams that average in the mid-single-digits on drugs that ultimately make it to market. The analyst reiterates a Buy rating and $230 price target on the stock.
News For LGND From the Last 2 Days
There are no results for your query LGND